Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 1:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 373 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Idiopathic Pulmonary Arterial Hypertension Clear all
Recruiting Not applicable Interventional

Right Ventricular Pacing in Pulmonary Arterial Hypertension

NCT04194632
View directory record Official record
Conditions
Pulmonary Artery Hypertension, Right Ventricular Dysfunction
Interventions
Temporary right ventricular pacing
Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 14, 2026, 1:49 AM EDT
Recruiting No phase listed Observational

Right Ventricle Lipid in Pulmonary Arterial Hypertension (PAH)

NCT05462574
View directory record Official record
Conditions
Idiopathic Pulmonary Arterial Hypertension, Heritable Pulmonary Arterial Hypertension, Pulmonary Arterial Hypertension Associated With Connective Tissue Disease
Interventions
No Intervention
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 14, 2026, 1:49 AM EDT
Completed Phase 3 Interventional Results available

A Study of Tadalafil in Pediatric Participants With Pulmonary Arterial Hypertension (PAH)

NCT01824290
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
Tadalafil, Placebo, ERA as specific PAH treatment
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
6 Months to 17 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
7
States / cities
Atlanta, Georgia • Detroit, Michigan • Cincinnati, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2021 · Synced Oct 14, 2026, 1:49 AM EDT
Recruiting No phase listed Observational

Pulmonary Hypertension Association Registry

NCT04071327
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension, Pulmonary Hypertension
Interventions
Not listed
Lead sponsor
Pulmonary Hypertension Association, Inc.
Other
Eligibility
0 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
52
States / cities
Phoenix, Arizona • Sacramento, California • San Francisco, California + 40 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Oct 14, 2026, 1:49 AM EDT
Completed Phase 4 Interventional Results available

Assess the Efficacy and Safety of Sildenafil When Added to Bosentan in the Treatment of Pulmonary Arterial Hypertension

NCT00323297
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Bosentan, Placebo, Sildenafil Citrate
Drug · Other
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
6
States / cities
Los Angeles, California • Detroit, Michigan • Pittsburgh, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Oct 14, 2026, 1:49 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Study of Pulmonary Hypertension Peripheral Limitations

NCT05968859
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Healthy
Interventions
Aerobic Training, Leg Training
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 14, 2026, 1:49 AM EDT
Recruiting No phase listed Observational

Understanding the Effects of Pulmonary Arterial Hypertension on Lean Muscle Mass

NCT07132788
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
blood draw, Short Performance Physical Battery, Grip strength test, Six minute walk test, Chest CT scan, Dual-Energy X-ray Absorptiometry Scan, Activity monitoring, 24 hour diet recall, Echocardiogram, Quality of Life Questionnaire (emPHasis 10), International Physical Activity Questionnaire Short Form (IPAQ-SF)
Diagnostic Test · Radiation · Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 14, 2026, 1:49 AM EDT
Completed Phase 2 Interventional Results available

FK506 (Tacrolimus) in Pulmonary Arterial Hypertension

NCT01647945
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Placebo, FK506 level < 2 ng/ml, FK506 level 2-3 ng/ml, FK506 level 3-5 ng/ml
Drug
Lead sponsor
Edda Spiekerkoetter
Other
Eligibility
18 Years to 70 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2016 · Synced Oct 14, 2026, 1:49 AM EDT
Completed Phase 3 Interventional

Mono vs. Dual Therapy for Pediatric Pulmonary Arterial Hypertension

NCT04039464
View directory record Official record
Conditions
Pediatric Pulmonary Hypertension
Interventions
Mono-Therapy with Sildenafil, Duo-Therapy with Sildenafil + Bosentan
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
3 Months to 18 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
10
States / cities
Aurora, Colorado • St. Petersburg, Florida • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Oct 14, 2026, 1:49 AM EDT
Terminated Phase 4 Interventional Results available

Treprostinil Combined With Tadalafil for Pulmonary Hypertension

NCT01302444
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Tadalafil, Placebo
Drug
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
9
States / cities
Portland, Maine • Boston, Massachusetts • Newark, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2013 · Synced Oct 14, 2026, 1:49 AM EDT
Terminated Phase 2 Interventional

A Phase 2 Study to Determine the Safety and Efficacy of AIR001 in Subjects With Pulmonary Arterial Hypertension (PAH)

NCT01725256
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
AIR001 (sodium nitrite inhalation solution)
Drug
Lead sponsor
Aires Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
17
States / cities
La Jolla, California • Torrance, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2014 · Synced Oct 14, 2026, 1:49 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study of Treprostinil to Treat Interstitial Lung Disease Pulmonary Hypertension

NCT05564637
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Interstitial Lung Disease, Healthy Adults
Interventions
Treprostinil, Right Heart Catheterization (RHC) while exercising, Optional Muscle Biopsy
Drug · Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Oct 14, 2026, 1:49 AM EDT
Completed Phase 3 Interventional Results available

BAY63-2521:Long-term Extension Study in Patients With Pulmonary Arterial Hypertension

NCT00863681
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
Riociguat (BAY63-2521)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 80 Years
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
11
States / cities
Los Angeles, California • Sacramento, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 14, 2026, 1:49 AM EDT
Completed Phase 4 Interventional Results available

Epoprostenol for Injection in Pulmonary Arterial Hypertension - Extension of AC-066A401

NCT01105117
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
ACT-385781A (Actelion Epoprostenol), Flolan®
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
7
States / cities
La Jolla, California • Aurora, Colorado • Durham, North Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2012 · Synced Oct 14, 2026, 1:49 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)

NCT02138825
View directory record Official record
Conditions
Idiopathic Interstitial Pneumonias / Hypertension,Pulmonary
Interventions
Riociguat (Adempas, BAY63-2521), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 80 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
17
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2017 · Synced Oct 14, 2026, 1:49 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Pilot Study of the Safety and Efficacy of Carvedilol in Pulmonary Arterial Hypertension

NCT00964678
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Carvedilol
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 8, 2017 · Synced Oct 14, 2026, 1:49 AM EDT
Terminated Phase 4 Interventional Results available

Effects of Oral Sildenafil on Mortality in Adults With PAH

NCT02060487
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
sildenafil citrate
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 74 Years
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
11
States / cities
Atlanta, Georgia • Grand Rapids, Michigan • Wooster, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated May 13, 2022 · Synced Oct 14, 2026, 1:49 AM EDT
Completed Phase 3 Interventional

Study to Assess the Longterm Safety of Sildenafil Citrate in Patients With Pulmonary Arterial Hypertension

NCT00159887
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Sildenafil citrate
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
24
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Oct 14, 2026, 1:49 AM EDT
Completed Phase 3 Interventional Results available

Study the Safety and Effectiveness of Tadalafil on High Blood Pressure in the Blood Vessel Going From the Heart to the Lungs

NCT00549302
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
tadalafil
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Years and older
Enrollment
357 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Bend, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 9, 2013 · Synced Oct 14, 2026, 1:49 AM EDT
Completed Phase 2 Interventional Results available

Estrogen Receptor Antagonist in Patients With Pulmonary Arterial Hypertension

NCT02911844
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Fulvestrant
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 9, 2019 · Synced Oct 14, 2026, 1:49 AM EDT
Terminated Not applicable Interventional

Ambrisentan for the Improvement in Right Ventricular Strain in Scleroderma Associated Pulmonary Arterial Hypertension

NCT02169752
View directory record Official record
Conditions
Pre-Pulmonary Atrial Hypertension
Interventions
Ambrisentan
Drug
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years to 80 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Oct 14, 2026, 1:49 AM EDT
Terminated Not applicable Interventional Results available

Iloprost for the Treatment of Pulmonary Hypertension in Adults With Congenital Heart Disease

NCT01319045
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Congenital Heart Disease, Eisenmenger's Syndrome
Interventions
Iloprost
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 26, 2015 · Synced Oct 14, 2026, 1:49 AM EDT
Active, not recruiting Phase 2 Interventional

Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension

NCT02682511
View directory record Official record
Conditions
Scleroderma, Diffuse, Scleroderma, Systemic, Scleroderma, Limited, Sclerosis, Progressive Systemic, Skin Diseases, Connective Tissue Diseases, Pathologic Processes, Autoimmune Diseases
Interventions
Oral Ifetroban, Oral Placebo
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
10
States / cities
Tucson, Arizona • Los Angeles, California • Weston, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 14, 2026, 1:49 AM EDT